FIELD: biotechnology.
SUBSTANCE: described is a group of inventions including a composition of T cells to be applied in treatment of cancer in an individual, a method for treating cancer in an individual (variants). The composition of T cells includes selectively grafted T cells targeting clonal neoantigens characteristic of cancer in an individual, wherein the clonal neoantigen has a 95% confidence interval of the cancer cell fraction (CCF) greater than or equal to 0.75. In one of the implementation variants, the cancer constitutes a non-small-cell lung cancer (NSCLC) or melanoma.
EFFECT: invention expands the range of means of treating cancer.
23 cl, 5 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD | 2016 |
|
RU2739036C2 |
| SELECTING CANCER MUTATIONS TO CREATE PERSONALIZED CANCER VACCINE | 2019 |
|
RU2809620C2 |
| METHODS FOR PREDICTION OF APPLICABILITY OF PROTEINS OR PROTEIN FRAGMENTS FOR IMMUNOTHERAPY | 2017 |
|
RU2782336C2 |
| METHODS OF TREATING CANCER USING ACTIVATED T-CELLS | 2016 |
|
RU2729362C2 |
| IDENTIFICATION, PRODUCTION AND USE OF NEOANTIGENS | 2016 |
|
RU2729116C2 |
| COMPOSITIONS AND METHODS FOR PRODUCING T-CELLS | 2018 |
|
RU2793344C2 |
| METHODS AND COMPOSITIONS FOR TREATING TUMORS | 2017 |
|
RU2741786C2 |
| METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | 2018 |
|
RU2799341C2 |
| COMPOSITIONS OF VACCINES AGAINST NEOPLASIA AND METHODS FOR OBTAINING THEREOF | 2016 |
|
RU2753246C2 |
| NEOANTIGENS AND THEIR APPLICATION METHODS | 2017 |
|
RU2773273C2 |
